Orchid Pharma's Investor Presentation for Q1 FY27 highlights robust financial results.

Consolidated revenue for the quarter reached ₹153.13 Cr, growing from ₹138.53 Cr year-over-year.

Profitability saw a sharp increase, with consolidated EBITDA at ₹23.98 Cr (vs ₹12.23 Cr YoY) and PAT at ₹8.67 Cr (vs ₹3.83 Cr YoY). This boosted EBITDA margin to 15.7% and PAT margin to 5.7%. Operationally, Dhanuka Laboratories Ltd. has been amalgamated into Orchid Pharma.

The overall sentiment reflects strong business performance driven by improved margins.